Does raising high-density lipoprotein cholesterol level benefit patients with coronary artery disease?
M John Chapman
Correspondence National Institute for Health and Medical Research, (INSERM) Unit 551, Pavillon Benjamin Delessert, Hôpital de la Pitié, 83 Boulevard de l'hôpital, Paris, Cedex 13, 75651, France.
Email chapman@chups.jussieu.fr
This article has no abstract so we have provided the first paragraph of the full text.
Trials have established that statin therapy to reduce LDL cholesterol prevents up to 35% of cardiovascular morbidity and mortality in common forms of atherogenic dyslipidemia. Although considerably reduced by statins, aspirin, 
-blockers and angiotensin-converting-enzyme inhibitors, residual cardiovascular risk remains high, especially in patients with CHD and type 2 diabetes. Therefore, an integrated therapeutic approach is required. Low HDL-cholesterol levels are an independent risk factor for CHD and are common in the general population.1 Screening for low HDL cholesterol during routine blood-lipid analyses seems warranted, therefore, but is sadly neglected in the new General Medical Services contract, which recommends targeting total plasma cholesterol only.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
